Capital Management Associates Inc lifted its stake in shares of Darden Restaurants, Inc. (NYSE: DRI) by 93.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,058 shares of the restaurant operator's stock after buying an additional 3,413 shares during the quarter.

DRI's multi-brand portfolio shows synchronized growth as all segments post positive comps, boosting revenues, traffic and positioning it ahead of peers.

These stocks that pay dividends consistently have the ability to generate long-term capital appreciation.

Shares of Darden Restaurants, Inc. (NYSE: DRI - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-seven brokerages that are currently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average 1-year price

Cullen Investment Group LTD. reduced its stake in shares of Darden Restaurants, Inc. (NYSE: DRI) by 39.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,423 shares of the restaurant operator's stock after selling 14,165 shares during the period. Cullen Investment Group

Darden Restaurants (DRI) maintains a buy rating as demand remains resilient and management accelerates new store openings. Q3 saw 6% y/y sales growth, with adjusted same-restaurant sales potentially near 5% absent weather and promotion headwinds. Management raised FY2026 new restaurant guidance and expects further acceleration in FY2027, signaling strong confidence in demand trends.

Clear Trail Advisors LLC purchased a new position in shares of Darden Restaurants, Inc. (NYSE: DRI) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 159,392 shares of the restaurant operator's stock, valued at approximately $29,331,000. Darden Restaurants makes up 6.8% of Clear Trail Advisors LLC's

DRI gains on menu innovation and strong sales, but inflation, high costs and weather disruptions continue to pressure margins.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, according to the KFF Health Tracking Poll.

Darden Restaurants, Inc. (NYSE: DRI) on Thursday posted better-than-expected earnings for the third quarter.